McGill Centre for Translational Research in Cancer, Canda
North Bristol NHS Trust Majorlijn Ligtenberg
Radboud University Medical Center, Netherlands Mary Porteous
University of Edinburgh
Our Science Advisory Committee consists of four independent members drawn from leading scientists broadly representing the programme diversity.
The committee meet annually, along with CRUK and PPI representation, to monitor progress and provide scientific evaluation of the CGCV program of research to the programme and work-package leads. The feedback received from the SAC is used to direct future research and program strategy.
The Patient Reference Panel (PRP) will be made up of 'research partners': patients, carers and members of the public who are affected by cancer and have an interest in genetics.
The PRP has been set up to for our research partners, working together with our research team, to look at how the CanGene-CanVar programme is set up and running, to make sure it is in the best interests of those who may be considering genetic testing, as well as making sure of good research outcomes.
Sheffield University Hospitals NHS Foundation Trust
Leeds Teaching Hospitals NHS Trust George Burghel
Manchester University NHS Foundation Trust James Drummond
Cambridge University Hospitals NHS Trust Ian Berry
Leeds Teaching Hospitals NHS Trust Andrew Wallace
Manchester University NHS Foundation Trust
CStAG is formed of NHS Clinical Laboratory Scientist representatives from across the UK.
The committee has been established from members of CanVIG, a group formed to improve the consistency of cancer genetic variant interpretation in the UK. The members are focussing the working priorities of CanVIG-UK and are an expert group of advisors supporting work-package 2.
Senior Lecturer St George's University of London
RCGP Joint Clinical Champion Genomics
GP Surrey Downs
GPwSI in Genetics, Yorkshire and Humber Genomics Medicine Centre; Primary Care Adviser to Health Education England Genomics Education Programme; RCGP Joint Clinical Champion in Genomics Medicine; GP, Shipley Medical Practice, Affinity Care
As RCGP Joint Clinical Champions in Genomics facilitating the adoption and diffusion of new knowledge within primary care, our panel leads have a wealth of expertise to contribute across the CGCV programme.
The wider panel membership remains flexible to suit the needs of programme, with Imran and Judith acting as a point of liaison between CGCV researchers and the primary care community. In particular, the panel are involved with external review of clinical guidelines developed in work-package 3.
University Hospital Southampton Foundation NHS Trust; Associate Professor in Medical Oncology, University of Southampton
Dr Copson is a practising medical oncologist interested in precision medicine and germline cancer susceptibility, as well as national lead for the oncogenetics training working party.
The oncology panel membership will be flexible to suit the different needs across the CGCV programme. In particular, our clinical education work-package (5) investigators will be collaborating with the oncogenetics training working party and oncologists will also be involved in external review of clinical guidelines developed in work-package 3.
The Clinical Guideline Group supports work package 3 and is formed of Clinical Genetics specialists representing all regions of the UK.
The group is involved at every stage of guideline development, as they review the evidence collated by work-package staff and establish consensus recommendations (clinical guidelines) for genetic testing and management of patients at elevated genetic risk of cancer.
The work of the group is also sent for external review by gene-specific experts, our primary care and oncology panels, work-package 4 genetic counsellor, and patient representatives.